Long-acting β2-agonist step-off in patients with controlled asthma.
Brozek Jan L, Kraft Monica, Krishnan Jerry A, +6 more·Archives of internal medicine
BACKGROUND: Because of concerns about the safety of long-acting β(2)-agonist (LABA) use in patients with asthma, withdrawal of the LABA is recommended by the US Food and Drug Administration once asthma is controlled by combination therapy with a LABA and inhaled corticosteroid (ICS). OBJECTIVE: To perform a syst…